About Movfor

MOVFOR is an oral experimental antiviral drug which contains Molnupiravir.

It exerts its antiviral action through introduction of copying errors during viral RNA replication.

As per the studies performed in covid-19 patients, Molnupiravir has shown to shorten the time to recovery in some people.

During this pandemic the Drug Controller General of India (DCGI) has granted an accelerated review and approval of Molnupiravir to meet the urgent medical need for the treatment of COVID-19 through restricted medical use.

MOVFOR can be used easily in Home quarantine Patients as well as Hospitalized cases.

about image
 
left image
right image

Frequently Asked Questions

A list of questions and answers relating to a particular subject, especially one giving
basic information for users of a website.

Covid-19 disease is now known to each & everyone. The impact that it has created in terms of loss of lives, sudden shutdown of economy, financial, emotional & physical losses will be engraved in History in coming times. COVID-19 is an infectious disease caused by the novel coronavirus.

Multiple variants of the virus that causes COVID-19 have been documented globally during the ongoing pandemic.

Viruses constantly change and become more diverse. Scientists monitor these changes, including changes to the spikes on the surface of the virus. By carefully studying viruses, scientists can learn how changes to the virus might affect how it spreads and how sick people will get from it.

So far six notable Covid-19 variants are discovered globally:

    B.1.617.2 (Delta)
  • First identified in India in December 2020. A mutated version, Delta plus variant is recently diagnosed in India.

    • B.1.1.7 (Alpha)
  • First detected in the United Kingdom near December 2020.

    • B.1.351 (Beta)
  • First detected in South Africa in December 2020.

    • P.1 (Gamma)
  • First identified in travelers from Brazil, who were tested during routine screening at an airport in Japan, in early January.

    • B.1.427 and B.1.429 (Epsilon)
  • First identified in California in February 2021.

    • B.1.1.529 (Omicron)
  • First identified in South Africa in November 2021

These variants seem to spread more easily and quickly than other variants, which may lead to more cases of COVID-19. An increase in the number of cases will put more strain on healthcare resources, leading to more hospitalizations, and potentially more deaths.

So far, studies suggest that the current authorized vaccines work on the circulating variants. Scientists will continue to study these and other variants.

Worldwide till now 18.1 crores of population has been affected with Covid 19, while India has reported 3.03 crores Covid cases till date since inception

People with COVID-19 have reported a wide range of symptoms ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. Anyone can have mild to severe symptoms. People with these symptoms may have COVID-19:

  • Fever or chills
  • Cough
  • Shortness of breath or difficulty breathing
  • Fatigue
  • Muscle or body aches
  • Headache
  • New loss of taste or smell
  • Sore throat
  • Congestion or runny nose
  • Nausea or vomiting
  • Diarrhea

This list does not include all possible symptoms it is based on newer rising variants. Older adults and people who have severe underlying medical conditions like heart, lung disease or diabetes seem to be at higher risk for developing more serious complications from COVID-19 illness.

Remdesivir
In severe Hospitalized cases

Favipiravir
In mild to moderate Hospitalized or non-Hospitalized cases

MOVFOR is an oral experimental antiviral drug which contains Molnupiravir. It exerts its antiviral action through introduction of copying errors during viral RNA replication.

As per the studies performed in covid-19 patients, Molnupiravir has shown to shorten the time to recovery in some people.

During this pandemic the Drug Controller General of India (DCGI) has granted an accelerated review and approval of Molnupiravir to meet the urgent medical need for the treatment of COVID-19 through restricted medical use.

MOVFOR can be used easily in Home quarantine Patients as well as Hospitalized cases with COVID-19 mild disease.

MOVFOR is to be taken orally in a dose of 800 mg (four 200 mg capsules) for 5 days.

The doctor may consider the days of treatment depending on Patient’s health condition. MOVFOR may help decrease the amount of the coronavirus in body. This may help the Patient recover faster.

The capsules should be swallowed whole with a sufficient amount of fluid (e.g., a glass of water). The capsules should not be opened, crushed or chewed.

Tell your healthcare provider about all of your medical conditions, including if you

  • Have any allergies
  • Have kidney or liver problems
  • Are pregnant or plan to become pregnant
  • Are breastfeeding or plan to breastfeed
  • Have any serious illnesses such as heart disease or diabetes
  • Have been taking any medications for any other illnesses
  • Are taking any medicines (prescription, over-the-counter, vitamins, or herbal products). Molnupiravir may affect the way other medicines work, and other medicines may affect how molnupiravir works.
  • Especially tell your healthcare provider if you are taking the medicines chloroquine phosphate or hydroxychloroquine sulfate.

Common side effects are diarrhea, nausea, dizziness and headache and uncommon or rare are vomiting, rash and hives.

There are no studies conducted in humans or animals with the use of Molnupiravir.

No study is performed in pregnant women. Hence there is no data available. Doctor will need to evaluate the situation and decide whether to use MOVFOR in these patients.

MOVFOR should not be given during breast feeding and for 4 days after the last dose of molnupiravir.

Tell your healthcare provider right away if you have any side effect that bothers you or does not go away.

You can report the side effects on Hetero helpline no. 1800-120-8689 or write us on drugsafetyindia@heterodrugs.com

 
testimonials
testimonials

Testimonials

A formal statement testifying to someone's character and qualifications.

slide image slide image slide image
slide image
 
footer image
Available in the Hospitals - All OVER INDIA
Available in the Hospitals All OVER INDIA